Pomalyst - Bristol Myers Squibb
- Manufacturer
- Bristol Myers Squibb
- Effective date
- 2025-02-26
- Label type
- RISK EVALUATION & MITIGATION STRATEGIES
- Version
- 6
- Source
- full-release
- Hydrated at
- 2026-06-04 22:50:39
Label at a glance#
Contacts and useful links#
Label contents#
Full prescribing information#
I. Administrative Information
Risk: embryo-fetal exposure
Initial Shared System REMS Approval: 02/2025
II. REMS Goals
The goals of PS-Pomalidomide REMS are as follows:
- To prevent the risk of embryo-fetal exposure to pomalidomide.
- To inform prescribers, patients, and pharmacists on the serious risks and safe-use conditions for pomalidomide.
III. REMS Requirements
Pomalidomide Applicants must ensure that healthcare providers, patients, and pharmacies comply with the following requirements:
1. Healthcare providers who prescribe pomalidomide must:
To become certified to prescribe |
|
Before treatment initiation (first prescription); within 10-14 days and again within 24 hours |
|
Before treatment initiation (first prescription) |
|
During treatment; weekly for at least the first 4 weeks |
|
During treatment; every 2 weeks after the first 4 weeks |
|
During treatment; every 4 weeks after the first 4 weeks |
|
During treatment: before each prescription |
|
At all times |
|
2. Females (adults and children) who can get pregnant who are prescribed pomalidomide:
Before treatment initiation; 4 weeks |
|
Before treatment initiation; within 10-14 days and again within 24 hours |
|
Before treatment initiation |
|
During treatment; weekly at least the first 4 weeks |
|
During treatment; before each prescription |
|
During treatment and after treatment discontinuation; for 4 weeks |
|
At all times |
|
3. Adult females who cannot get pregnant who are prescribed pomalidomide:
Before treatment initiation |
|
During treatment; before each prescription |
|
During treatment; every 6 months |
|
During treatment and after treatment discontinuation; for 4 weeks |
|
At all times |
|
4. Female children who cannot get pregnant who are prescribed pomalidomide:
Before treatment initiation |
|
During treatment; before each prescription |
|
During treatment and after treatment discontinuation; for 4 weeks |
|
At all times |
|
5. Males (adults and children) who are prescribed pomalidomide:
Before treatment initiation |
|
During treatment; before each prescription |
|
During treatment and after treatment discontinuation; for 4 weeks |
|
At all times |
|
6. Pharmacies that dispense pomalidomide must:
To become certified to dispense |
|
Before dispensing |
|
After dispensing |
|
At all times |
|
REMS Applicant Requirements
Pomalidomide Applicants must provide training to healthcare providers who prescribe pomalidomide.
The training must include the following educational materials: Welcome Letter, Prescriber Guide, and REMS Education and Prescribing Safety Kit. The training must be available online and hardcopy format via mail.
Pomalidomide Applicants must provide training to pharmacies that dispense pomalidomide.
The training includes the following educational materials: Pharmacy Guide, Education and Counseling Checklist for Pharmacies, REMS Program Pharmacy Training, and Pharmacy Certification Quiz. The training must be available online and hardcopy format via mail.
To support REMS Program operations, Pomalidomide Applicants must:
- Distribute pomalidomide only to certified pharmacies.
- Ensure participating pharmacies are able to certify by contracting with the manufacturer and agreeing to comply with the requirements of the REMS Program.
- Establish and maintain the REMS Program websites,
www.PS-PomalidomideREMS.com and
www.BMSREMSPatientSafety.com. The REMS Program websites must include the capability to complete prescriber certification online, to enroll and to take REMS surveys online, and the option to print the Prescribing Information, Medication Guide, and REMS materials. All product websites for consumers and healthcare providers must include prominent REMS-specific links to the REMS Program website. The REMS Program website must not link back to the promotional product website(s). - Make the REMS Program websites fully operational and all REMS materials available through
www.PS-PomalidomideREMS.com,
www.BMSREMSPatientSafety.com, or by calling PS-Pomalidomide REMS within 90 calendar days of approval. - Establish and maintain the REMS Call Center for REMS participants at 1-888-423-5436.
- Establish and maintain a validated, secure database of all REMS participants who are enrolled and/or certified in the REMS Program.
- Ensure prescribers are able to enroll and enroll patients into the REMS Program by phone, fax, or online.
- Ensure prescribers are able to complete prescriber surveys by phone and online.
- Ensure prescribers are able to obtain an authorization number by phone and online. For females who can get pregnant, the authorization is valid for 7 days from the date of the last pregnancy test. For all other patients, the authorization number is valid for 30 days from the date the authorization number is issued.
- Ensure patients are able to take patient surveys by phone and online.
- Ensure pharmacies are able to obtain dispense confirmation numbers by phone or online.
- Ensure prescribers, patients, and pharmacists are able to report pregnancies by phone, fax, and online.
- Provide Prescriber Enrollment Form, Prescriber Guide and the Prescribing Information to REMS participants who (1) attempt to prescribe pomalidomide and are not yet certified or (2) inquire about how to become certified.
- Notify prescribers within 24 hours after they become certified in the REMS Program.
- Notify prescribers when patient enrollment is confirmed by fax and online.
- Provide certified prescribers access to the database of their enrolled patients and certified pharmacies.
- Provide certified pharmacies access to the REMS system.
- Establish and maintain a registry which includes a reporting and collection system for female patients or female partners of male patients receiving pomalidomide to provide information on pregnancy outcomes and root cause of pregnancy.
- Ensure that once a report of a pregnancy is received, PS-Pomalidomide REMS follows up to obtain all required data for the registry.
To ensure REMS participants’ compliance with the REMS Program, Pomalidomide Applicants must:
- Maintain adequate records to demonstrate that REMS requirements have been met, including, but not limited to records of: pomalidomide prescribing and dispensing; enrollment and certification of prescribers and pharmacies; enrollment, appropriate risk categorization, and pregnancy testing results of patients; and audits of pharmacies. These records must be readily available for FDA inspections.
- Establish a plan for addressing noncompliance with REMS program requirements.
- Ensure patients who discontinue treatment for 12 consecutive months must re-enroll in the REMS.
- Monitor prescribers, pharmacies, and patients on an ongoing basis to ensure the requirements of the REMS are being met. Take corrective action if noncompliance is identified, including de-certification.
- Monitor and ensure that patients have been assigned correctly to one of the following patient risk categories. Confirm risk category during the patient enrollment process:
- Adult female who can get pregnant: all females who are menstruating, amenorrheic from previous medical treatments, under 50 years, and/or perimenopausal.
- Female child who can get pregnant: all females under 18 years who are menstruating.
- Adult female who cannot get pregnant: females who have had a natural menopause for at least 24 consecutive months, a hysterectomy, and/or bilateral oophorectomy.
- Female child who cannot get pregnant: all females under 18 years who are not menstruating.
- Adult male: 18 years or older
- Male child: under 18 years
- Audit all pharmacies within 3 months of first dispense of pomalidomide, annually for the first 2 years, and at least once every three years thereafter. For pharmacies that have been in the program for more than two years, a risk-based assessment is performed to select which pharmacies are audited.
- Take reasonable steps to improve implementation of and compliance with the requirements in PS-Pomalidomide REMS based on monitoring and evaluation of the PS-Pomalidomide REMS.
IV. REMS Assessment Timetable
Pomalidomide NDA Applicants must submit REMS assessments August 3, 2016 and every two years thereafter. To facilitate inclusion for as much information as possible while allowing reasonable time to prepare the submission, the reporting interval covered by each assessment should conclude no earlier than 60 days before the submission date for that assessment. Pomalidomide NDA Applicants must submit each assessment so it will be received by the FDA on or before the due date.
V. REMS Materials
The following materials are part of PS-Pomalidomide REMS:
Enrollment Forms
Prescriber:
- Prescriber Enrollment Form
Patient:
- Patient-Physician Agreement Form for Adult Female Who Can Get Pregnant
- Patient-Physician Agreement Form for Female Child Who Can Get Pregnant
- Patient-Physician Agreement Form for Adult Female Who Can Not Get Pregnant
- Patient-Physician Agreement Form for Female Child Who Can Not Get Pregnant
- Patient-Physician Agreement Form for Adult Male
- Patient-Physician Agreement Form for Male Child
Training and Educational Materials
Prescriber:
- Welcome Letter
- Prescriber Guide
- REMS Education and Prescribing Safety Kit
Pharmacy:
- Pharmacy Guide
- REMS Program Pharmacy Training
- Pharmacy Certification Quiz
Patient:
- Patient Guide
- Patient Resource Pack Envelope
Patient Care Forms
- Education and Counseling Checklist for Pharmacies
Other Materials
- REMS Program Website
- BMS REMS Patient Safety Website
VI. Statutory Elements
This REMS is required under section 505-1 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21U.S.C. 355-1) and consists of the following elements:
- Elements to Assure Safe Use (ETASU):
- Healthcare providers who prescribe pomalidomide are specially certified under 505-1(f)(3)(A)
- Pharmacies and healthcare settings that dispense pomalidomide are specially certified under 505-1(f)(3)(B)
- Pomalidomide is dispensed to patients with evidence or other documentation of safe-use conditions under 505-1(f)(3)(D)
- Each patient using pomalidomide is subject to certain monitoring under 505-1(f)(3)(E)
- Each patient using pomalidomide is enrolled in the PS-Pomalidomide REMS Program/Registry under 505-1(f)(3)(F)
- Implementation System
- Timetable for Submission of Assessments
DailyMed Product Concepts#
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| 191ddea2-3e27-5c8d-dccc-59ef9a0abcf7 | Product name | 2 | 20250401 |
DailyMed REMS / Drug Safety Documents#
Labels related to this REMS document
| DailyMed label | Relation | Version | Effective | Manufacturer | Source |
|---|---|---|---|---|---|
| These highlights do not include all the information needed to use POMALYST safely and effectively. See full prescribing information for POMALYST. POMALYST ® (pomalidomide) capsules, for oral use Initial U.S. Approval: 2013 | SPL related document | 2025-02-26 | Celgene Corporation | 20250529_8af8f9d1-87fa-4b8c-9c62-afed574185d9.zip!cf1da3a0-0c3f-48c4-a8d1-d65b3d853e68.xml |
Products#
Every source-derived product name is available through these pages.
- Pomalyst
- pomalidomide
- Celgene Corporation
Source Document#
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Pomalyst | POMALIDOMIDE | Celgene Corporation | 2b25ef01-5c9e-11e1-b86c-0800200c9a66 | 2025-02-26 | Boxed warning, Warnings, Adverse reactions | Pomalyst |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.